Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe. Anji’s asset-centric business model allows for speed and flexibility in building value, leveraging a clinical and regulatory core that operates with “hub-and-spoke" efficiency. Anji’s clinical pipeline includes gut-targeted metformin (ANJ900 in Phase 3) intended for glucose management in patients with type 2 diabetes and advanced chronic kidney disease, as well as pradigastat (ANJ908 in Phase 2) for treatment of functional constipation. For more info, visit www.anjipharma.com. For legal matters, Anji is advised by Foley Hoag LLP, a seasoned team deeply rooted in the Boston-area entrepreneurial ecosystem. Anji’s capital markets, business development, and investor relations are managed by Locust Walk, a global life science transaction firm that uniquely integrates strategy consulting and investment banking to provide actionable strategic advice and deal and capital markets execution.